Latest papers

Human CMV vaccine trials: what if CMV caused a rash?

Development of breeding populations of rhesus macaques (Macaca mulatta) that are specific pathogen-free for rhesus cytomegalovirus.

Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus.

Cytomegalovirus vaccine development.

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.

Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy.

Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection.

[Human cytomegalovirus and congenital virus infection].

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Cytomegalovirus infection: the state of the art.

Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.

Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on.

Vaccine strategies against human cytomegalovirus infection.

DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates.

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients.

Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine.

Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).

Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.